ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0714

Therapeutic Dilemmas in Patients with ANCA-associated Vasculitis: Diffuse Alveolar Hemorrhage, Venous Thromboembolism and Anticoagulation

Elif Ediboglu1, Samuel Falde1, Misbah Baqir1, Rodrigo Cartin-Ceba2, Robert McBane1 and Ulrich Specks1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Scottsdale, AZ

Meeting: ACR Convergence 2024

Keywords: ANCA, ANCA associated vasculitis, Inflammation, pulmonary, Wegener's

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an acutely life-threating presentation of ANCA-associated vasculitis (AAV), and patients with AAV are at increased risk of venous thromboembolic events (VTE) at the time of active disease. We aimed to identify the clinical characteristics, management, and prognosis of patients with AAV and concurrent DAH and VTE.

Methods: This is a retrospective observational study. Patients diagnosed with AAV between 1997 and 2023 at Mayo Clinic who had a documented diagnosis of VTE (by radiologic reports) and concurrent DAH (diagnosed based on pathologic, bronchoscopic and/or radiologic reports) were included in the study.

Results: Fourteen patients presenting with DAH and VTE treated at Mayo Clinic were included. Patients were predominantly male (71%) with median age (IQR) at diagnosis of 67 (56-72). Nine patients (64%) had PR3-ANCA and 5 (36%) had MPO-ANCA. Five patients were diagnosed with DAH followed by VTE, 4 patients were diagnosed with VTE before developing DAH, and 5 patients were diagnosed with VTE and DAH simultaneously. IVC filters were placed in 13 patients (93%). All patients received anticoagulation adapted according to the clinical situation. One patient who had pre-existing interstitial lung disease died of respiratory failure after presenting with pulmonary embolism and subsequently developing DAH during the hospitalization. Six patients (43%) developed major bleeding (DAH or retroperitoneal hematoma) and three (21%) developed progression or recurrence of VTE within 90 days.

Conclusion: In patients with AAV, clinicians should follow guidelines for routine prevention of VTE and have a low index of suspicion for VTE in patients presenting with compatible symptoms.  Management of patients with DAH and VTE is challenging, and early IVC filter placement may facilitate management of these patients. Further therapies should be guided should be guided by the severity of DAH, additional organ manifestations of AAV, and risk stratification of the presenting VTE.

Supporting image 1

Supporting image 2


Disclosures: E. Ediboglu: None; S. Falde: None; M. Baqir: None; R. Cartin-Ceba: None; R. McBane: None; U. Specks: Amgen, 2, 5, Argenx, 2, AstraZeneca, 1, 2, 5, Boehringer-Ingelheim, 1, 2, Bristol-Myers Squibb(BMS), 5, CSL Vifor, 1, Genentech, 5, GlaxoSmithKline(GSK), 5, Northstar Medical Radioisotopes, 5, Novartis, 5, NS Pharma, 5.

To cite this abstract in AMA style:

Ediboglu E, Falde S, Baqir M, Cartin-Ceba R, McBane R, Specks U. Therapeutic Dilemmas in Patients with ANCA-associated Vasculitis: Diffuse Alveolar Hemorrhage, Venous Thromboembolism and Anticoagulation [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/therapeutic-dilemmas-in-patients-with-anca-associated-vasculitis-diffuse-alveolar-hemorrhage-venous-thromboembolism-and-anticoagulation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-dilemmas-in-patients-with-anca-associated-vasculitis-diffuse-alveolar-hemorrhage-venous-thromboembolism-and-anticoagulation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology